Valneva's 15min chart shows KDJ Death Cross, Bearish Marubozu formation.

Valneva's 15-minute chart has triggered a KDJ Death Cross and a Bearish Marubozu at 10/10/2025 12:15, indicating a shift in the momentum of the stock price towards the downside. This suggests that the stock is likely to continue to decrease, with sellers controlling the market. The bearish momentum is expected to persist.

Valneva's (VLA) stock experienced a significant decline on October 10, 2025, after the company announced a delay in the release of Phase 3 Lyme disease vaccine data and revised its financial outlook for 2025. The shares fell by 7% as investors reacted to the news, which was further compounded by the U.S. FDA's suspension of the product license for its IXCHIQ vaccine Valneva Shares Slide After FDA Suspension Prompts Guidance Revision^[3].

The delay in the Phase 3 data release, which was previously expected in late 2025, has now been pushed back to the first half of 2026. Additionally, Valneva has cut its annual revenue guidance for 2025 from €180-190 million to €165-180 million, with R&D investments reduced from €90-100 million to €80-90 million Valneva falls after Lyme disease vaccine data delay, outlook cut^[1]. The company attributed the delay and the downward revision to ongoing uncertainty regarding the IXCHIQ vaccine's suspension.

The stock's technical indicators also suggest a bearish trend. Valneva's 15-minute chart triggered a KDJ Death Cross and a Bearish Marubozu at 12:15 on October 10, 2025, indicating a shift in momentum towards the downside. This suggests that the stock is likely to continue to decrease, with sellers controlling the market C3is Inc. closes $2 million registered direct offering^[2].

Despite the challenges, Valneva has secured a new debt facility of up to $500 million with Pharmakon Advisors, LP. The first $215 million tranche will be used to repay existing debt, while the remaining $285 million will support future growth initiatives. The new financing package extends the company's debt maturity profile from Q1 2026 to Q4 2030 Valneva Shares Slide After FDA Suspension Prompts Guidance Revision^[3].

Valneva's Phase 3 trial for its Lyme disease vaccine candidate, co-developed with Pfizer (PFE), is progressing as planned, with regulatory submissions expected in 2026 and a potential market launch in the second half of 2027, pending approval Valneva Shares Slide After FDA Suspension Prompts Guidance Revision^[3].